Read the original post:
Celularity Releases CEO Letter to Shareholders
Related Post
- BioSyent Releases Financial Results for Q1 2024 - May 19th, 2024
- BioSyent Declares Second Quarter 2024 Dividend - May 19th, 2024
- HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress - May 19th, 2024
- Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise - May 19th, 2024
- Chemomab Therapeutics to Participate in Upcoming Scientific Conferences - May 19th, 2024
- QuTEM Receives GMP Certificates and Manufacturing Permits for Transmission Electron Microscopy Laboratory from the Swedish Medical Products Agency - May 19th, 2024
- Telix Files Registration Statement for Proposed Initial Public Offering in the United States - May 19th, 2024
- Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase - May 19th, 2024
- Tilray Brands Announces At-The-Market Program to Fund Strategic and Accretive Acquisitions and Accelerate Expansion Plan Upon U.S. Cannabis... - May 19th, 2024
- Intercept Presents New Data Demonstrating the Impact of OCA-Bezafibrate Combination Therapy on ALP and Metabolic Outcomes After Six Months of... - May 19th, 2024
- Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET - May 19th, 2024
- Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine - May 18th, 2024
- Recce Pharmaceuticals Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial - May 18th, 2024
- Aeterna Zentaris Announces Details Regarding Transaction with Ceapro - May 18th, 2024
- Innovative Fingerprint Drug Screening Solution Showcased at the UK's Premier Health and Safety Event - May 18th, 2024
- Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting - May 18th, 2024
- Spectral AI Announces Purchases of Over 100,000 Shares by Insiders - May 18th, 2024
- HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees - May 18th, 2024
- Assertio to Participate in Benchmark Healthcare Conference on May 21-22 - May 18th, 2024
- Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ - May 18th, 2024
- BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024 - May 18th, 2024
- More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024 - May 18th, 2024
- Better Choice Company Announces First Quarter 2024 Results - May 18th, 2024
- Recludix Pharma Presents Data Demonstrating Oral STAT3 Inhibitors Drive Differentiated Efficacy and Safety in Preclinical Models of Th17 Mediated Skin... - May 18th, 2024
- Kamari Pharma Announces New Data Presented at the 81st Annual Meeting of the Society for Investigative Dermatology - May 18th, 2024
- NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations - May 18th, 2024
- DBV Technologies Announces Plan to Implement ADS Ratio Change - May 18th, 2024
- Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day - May 18th, 2024
- Plus Therapeutics Announces New Employment Inducement Grants - May 18th, 2024
- Oculis updates share capital for its existing at-the-market offering program - May 18th, 2024
- Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action - May 18th, 2024
- Kane Biotech Expands its Wound Care Portfolio with Patented Schultz Biofilm Wound Map - May 15th, 2024
- Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member - May 15th, 2024
- Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - May 15th, 2024
- Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024 - May 15th, 2024
- CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates - May 15th, 2024
- Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates - May 15th, 2024
- Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase - May 15th, 2024
- Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update - May 15th, 2024
- Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis - May 15th, 2024
- PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results - May 15th, 2024
- Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - May 15th, 2024
- Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual... - May 15th, 2024
- Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss - May 15th, 2024
- PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101 - May 15th, 2024
- Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS - May 15th, 2024
- Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement - May 15th, 2024
- Yield10 Bioscience Announces Delisting from Nasdaq - May 15th, 2024
- Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA - May 15th, 2024
- Alvotech S.A. Annual General Meeting to be held June 7, 2024 - May 15th, 2024
- PHAXIAM provides Business and Financial Update for the First Quarter of 2024 - May 15th, 2024
- Avalyn Announces Multiple Presentations on its Lead Program, AP01, for Pulmonary Fibrosis and its Approach to Developing Novel Inhaled Therapies for... - May 13th, 2024
- IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024 - May 13th, 2024
- Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update - May 13th, 2024
- Oncocyte to Announce First Quarter 2024 Financial Results - May 13th, 2024
- Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference - May 13th, 2024
- Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT) - May 13th, 2024
- Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance - May 13th, 2024
- Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair... - May 13th, 2024
- Humacyte to Participate at Upcoming Investor Conferences in May - May 13th, 2024
- X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference - May 13th, 2024
- Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates - May 13th, 2024
- Jasper Therapeutics Announces Briquilimab Development Program in Asthma - May 13th, 2024
- Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies... - May 13th, 2024
- Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update - May 13th, 2024
- TransCode Therapeutics Open Letter to Shareholders - May 13th, 2024
- Biomerica Announces inFoods® IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024 - May 13th, 2024
- Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024 - May 13th, 2024
- Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH... - May 13th, 2024
- Relay Therapeutics to Host New Program and Platform Event on June 6, 2024 - May 13th, 2024
- Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference - May 13th, 2024
- Ocugen to Present at May 2024 Investor Conferences - May 11th, 2024
- PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine - May 11th, 2024
- Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024 - May 11th, 2024
- Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update - May 11th, 2024
- Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product - May 11th, 2024
- iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates - May 11th, 2024
- Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates - May 11th, 2024
- CorMedix Inc. to Participate in Two Upcoming Investor Conferences - May 11th, 2024
- Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation - May 11th, 2024
Recent Comments